Literature DB >> 15080302

The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome.

.   

Abstract

By using peripheral blood samples from 221 cases of severe acute respiratory syndrome (SARS), 34 of Mycoplasma pneumoniae infection, and 44 healthy adults, we measured the total number of natural killer (NK) and CD158b+ NK cells (CD158b+ NK) using flow cytometric analysis and calculated the percentage of CD158b+ NK cells. The total number of NK and CD158b+ NK cells and the percentage of CD158b+ NK cells were significantly lower in patients with SARS than in those with M. pneumoniae infection (P < .05 for all) and healthy subjects (P < .01, P < .01, P < .05, respectively); in 72 patients with severe SARS than in 149 with mild SARS (P < .05 for all); and in 174 cases of SARS with anti-SARS coronavirus-specific IgG and/or IgM antibodies than in 47 without antibodies (P < .05, P < .01, P < .01, respectively). There were no significant differences for the 3 values among patients with SARS without anti-SARS coronavirus antibody, patients with M. pneumoniae infection, and healthy subjects. The number of NK cells and the expression of CD158b on the surface of NK cells changed in patients with SARS and correlated with disease severity and the presence of anti-SARS coronavirus-specific antibodies; SARS differed from M. pneumoniae infection in pathogenesis involving NK cells. Monitoring the total number of NK and CD158b+ NK cells and the percentage of CDD158b+ NK cells might aid in differentiating SARS from M. pneumoniae infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080302      PMCID: PMC7110090          DOI: 10.1309/WPK7-Y2XK-NF4C-BF3R

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  44 in total

Review 1.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

2.  Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003.

Authors:  Yi-Ming Arthur Chen; Shu-Yuan Liang; Yi-Ping Shih; Chia-Yen Chen; Yuan-Ming Lee; Ling Chang; Shiao-Ying Jung; Mei-Shang Ho; Kung-Yee Liang; Hour-Young Chen; Yu-Jiun Chan; Da-Chen Chu
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

Review 3.  Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.

Authors:  Clara Di Vito; Francesca Calcaterra; Nicolò Coianiz; Sara Terzoli; Antonio Voza; Joanna Mikulak; Silvia Della Bella; Domenico Mavilio
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

4.  Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.

Authors:  Alessio Mazzoni; Lorenzo Salvati; Laura Maggi; Manuela Capone; Anna Vanni; Michele Spinicci; Jessica Mencarini; Roberto Caporale; Benedetta Peruzzi; Alberto Antonelli; Michele Trotta; Lorenzo Zammarchi; Luca Ciani; Leonardo Gori; Chiara Lazzeri; Andrea Matucci; Alessandra Vultaggio; Oliviero Rossi; Fabio Almerigogna; Paola Parronchi; Paolo Fontanari; Federico Lavorini; Adriano Peris; Gian Maria Rossolini; Alessandro Bartoloni; Sergio Romagnani; Francesco Liotta; Francesco Annunziato; Lorenzo Cosmi
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 5.  Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.

Authors:  Puja Kumari; Kajal Rawat; Lekha Saha
Journal:  Curr Pharmacol Rep       Date:  2020-07-18

6.  Cell-Mediated Immune Responses to COVID-19 Infection.

Authors:  Amélie Guihot; Elena Litvinova; Brigitte Autran; Patrice Debré; Vincent Vieillard
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

7.  Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial.

Authors:  Ivan Delgado-Enciso; Juan Paz-Garcia; Carlos E Barajas-Saucedo; Karen A Mokay-Ramírez; Carmen Meza-Robles; Rodrigo Lopez-Flores; Marina Delgado-Machuca; Efren Murillo-Zamora; Jose A Toscano-Velazquez; Josuel Delgado-Enciso; Valery Melnikov; Mireya Walle-Guillen; Hector R Galvan-Salazar; Osiris G Delgado-Enciso; Ariana Cabrera-Licona; Eduardo J Danielewicz-Mata; Pablo J Mandujano-Diaz; José Guzman-Esquivel; Daniel A Montes-Galindo; Henry Perez-Martinez; Jesus M Jimenez-Villegaz; Alejandra E Hernandez-Rangel; Patricia Montes-Diaz; Iram P Rodriguez-Sanchez; Margarita L Martinez-Fierro; Idalia Garza-Veloz; Daniel Tiburcio-Jimenez; Sergio A Zaizar-Fregoso; Fidadelfo Gonzalez-Alcaraz; Laydi Gutierrez-Gutierrez; Luciano Diaz-Lopez; Mario Ramirez-Flores; Hannah P Guzman-Solorzano; Gustavo Gaytan-Sandoval; Carlos R Martinez-Perez; Francisco Espinoza-Gómez; Fabián Rojas-Larios; Michael J Hirsch-Meillon; Luz M Baltazar-Rodriguez; Enrique Barrios-Navarro; Vladimir Oviedo-Rodriguez; Martha A Mendoza-Hernandez; Emilio Prieto-Diaz-Chavez; Brenda A Paz-Michel
Journal:  Exp Ther Med       Date:  2021-06-29       Impact factor: 2.447

Review 8.  A brief molecular insight of COVID-19: epidemiology, clinical manifestation, molecular mechanism, cellular tropism and immuno-pathogenesis.

Authors:  Sweta Singh; Rakesh Pandey; Sarika Tomar; Raunak Varshney; Darshika Sharma; Gurudutta Gangenahalli
Journal:  Mol Cell Biochem       Date:  2021-06-30       Impact factor: 3.396

9.  Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients.

Authors:  Stéphanie Bibert; Nicolas Guex; Joao Lourenco; Thomas Brahier; Matthaios Papadimitriou-Olivgeris; Lauro Damonti; Oriol Manuel; Robin Liechti; Lou Götz; Jonathan Tschopp; Mathieu Quinodoz; Peter Vollenweider; Jean-Luc Pagani; Mauro Oddo; Olivier Hügli; Frédéric Lamoth; Véronique Erard; Cathy Voide; Mauro Delorenzi; Nathalie Rufer; Fabio Candotti; Carlo Rivolta; Noémie Boillat-Blanco; Pierre-Yves Bochud
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

10.  The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.

Authors:  Anahid Jewett
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.